去纤苷如何使用？

It is the first drug approved by the US FDA to treat severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic vein occlusion (VOD) who have received blood or bone marrow hematopoietic stem cell transplantation (HSCT) and are accompanied by renal or pulmonary function abnormalities. At the same time, the drug has also obtained "orphan drug" qualifications. So how is defibrinoside used?

1. How to use defibrinoside:

The recommended dose of defibrotide for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol.

Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days.

2. Medication instructions

Defibrotide must be diluted prior to infusion.

Prior to administration of defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor.

Defibrotide was administered by constant intravenous infusion over a 2-hour period.

Administer the diluted defibrotide solution using an infusion set equipped with a 0.2 μm in-line filter. Flush the intravenous administration line (peripheral or central) with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, before and immediately after administration.

Do not coadminister defibrotide with other intravenous medications at the same time and in the same intravenous line.

Precautions for defibrination:

1. Bleeding: Monitor the patient for bleeding. If significant bleeding occurs, withhold or discontinue defibrotide.

2. Hypersensitivity reaction: If severe or life-threatening allergic reaction occurs, discontinue, follow standard medical care, and monitor until signs and symptoms resolve.

Recommended related hot articles: /newsDetail/74986.html